Transitioning the Molecular Tumor Board from Proof of Concept to Clinical Routine: A German Single-Center Analysis

SIMPLE SUMMARY: Access to molecular cancer treatments outside of clinical trials is limited and the benefit of molecular-guided, individualized patient care in patients with cancer progression after standard treatment is unclear. We here present the four-year experience of one of Europe’s first Mole...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoefflin, Rouven, Lazarou, Adriana, Hess, Maria Elena, Reiser, Meike, Wehrle, Julius, Metzger, Patrick, Frey, Anna Verena, Becker, Heiko, Aumann, Konrad, Berner, Kai, Boeker, Martin, Buettner, Nico, Dierks, Christine, Duque-Afonso, Jesus, Eisenblaetter, Michel, Erbes, Thalia, Fritsch, Ralph, Ge, Isabell Xiang, Geißler, Anna-Lena, Grabbert, Markus, Heeg, Steffen, Heiland, Dieter Henrik, Hettmer, Simone, Kayser, Gian, Keller, Alexander, Kleiber, Anita, Kutilina, Alexandra, Mehmed, Leman, Meiss, Frank, Poxleitner, Philipp, Rawluk, Justyna, Ruf, Juri, Schäfer, Henning, Scherer, Florian, Shoumariyeh, Khalid, Tzschach, Andreas, Peters, Christoph, Brummer, Tilman, Werner, Martin, Duyster, Justus, Lassmann, Silke, Miething, Cornelius, Boerries, Melanie, Illert, Anna L., von Bubnoff, Nikolas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7962829/
https://www.ncbi.nlm.nih.gov/pubmed/33800365
http://dx.doi.org/10.3390/cancers13051151

Ejemplares similares

Ejemplares similares